JOHN REPINE, MD
Osteopathic Medicine at 16 Ave, Denver, CO
License number
Colorado 23136
Category
Osteopathic Medicine
Type
Pulmonary Disease
Address
Address
12605 E 16Th Ave, Denver, CO 80045
Phone
(720) 848-0000
(303) 493-7000
(303) 493-7000
Personal information
See more information about JOHN REPINE at radaris.comName
Address
Phone
70 Cherry Hills Farm Dr, Englewood, CO 80113
2275 Cherry Hills Farm Dr, Englewood, CO 80110
70 Cherry Hills Farm Dr, Englewood, CO 80110
Organization information
See more information about JOHN REPINE at bizstanding.comJohn Repine MD
4200 E 9 Ave, Denver, CO 80262
Industry:
Internist
Phone:
(303) 329-3066 (Phone)
John Edward Repine
Professional information
Professor At Univrsity Of Colorado
Position:
professor at univrsity of colorado
Location:
Greater Denver Area
Industry:
Research
Work:
univrsity of colorado
-
professor
John Edward Repine, Denver CO
Specialties:
Internal Medicine, Pulmonary Disease
Work:
University of Colorado
4200 E 9Th Ave, Denver, CO 80220
4200 E 9Th Ave, Denver, CO 80220
Education:
University of Minnesota, Twin Cities (1971)
Dr. John Repine, Aurora CO - MD (Doctor of Medicine)
Address:
12800 E 19Th Ave, Aurora 80045
12605 E 16Th Ave, Aurora 80045
(720) 848-0000 (Phone)
WEBB-WARING INSTITUTE
E 9Th Ave SUITE C322, Denver 80220
(303) 315-6251 (Phone), (303) 315-8541 (Fax)
12605 E 16Th Ave, Aurora 80045
(720) 848-0000 (Phone)
WEBB-WARING INSTITUTE
E 9Th Ave SUITE C322, Denver 80220
(303) 315-6251 (Phone), (303) 315-8541 (Fax)
Hospitals:
12800 E 19Th Ave, Aurora 80045
12605 E 16Th Ave, Aurora 80045
WEBB-WARING INSTITUTE
E 9Th Ave SUITE C322, Denver 80220
University of Colorado Hospital - Anschutz Inpatient Pavilion
12605 East 16Th Avenue Dr, Aurora 80045
12605 E 16Th Ave, Aurora 80045
WEBB-WARING INSTITUTE
E 9Th Ave SUITE C322, Denver 80220
University of Colorado Hospital - Anschutz Inpatient Pavilion
12605 East 16Th Avenue Dr, Aurora 80045
Education:
Medical Schools
University of Mn Med Sch
Graduated: 1971
University of Mn Med Sch
Graduated: 1971
John Edward Repine, Aurora CO
Specialties:
Internist
Address:
13611 E Colfax Ave, Aurora, CO 80045
4200 E 9Th Ave, Denver, CO 80262
4200 E 9Th Ave, Denver, CO 80262
Methods Of Modulating Inflammatory Reactions By Modulating Xanthine Oxidoreductase Activity
US Patent:
2007022, Sep 27, 2007
Filed:
Sep 27, 2004
Appl. No.:
10/573354
Inventors:
Richard Wright - Denver CO, US
John Repine - Denver CO, US
John Repine - Denver CO, US
International Classification:
A61K 31/519, A61K 33/24, C12N 9/02
US Classification:
424617000, 435189000, 514262100
Abstract:
Evidence is presented that inflammation and injury involves activation of xanthine oxidoreductase (XOR) in the newly recruited mononuclear phagocytes (MNP). XOR has been shown to be increased predominantly in the MNP that increase rapidly in the lungs of rats that develop acute lung injury (ALI) following intratracheal cytokine insufflation. XOR was recovered from the MNP largely converted to its oxygen radical generating, reversible O-form, and alveolar MNP exhibited increased oxidative stress as evidenced by increased nitrotyrosine staining. Cytokine insufflation also increased alveolar cell apoptosis. A functional role for XOR in cytokine induced inflammation was demonstrated. Tungsten and allopurinol decreased MNP XOR induction, nitrotyrosine staining, inflammatory cell infiltration, and alveolar cell apoptosis. Transfer of control or allopurinol treated MNP into rat lungs and confirmed a specific role for MNP XOR in promoting lung inflammation. These data indicate that XOR can contribute to lung inflammation by its expression and conversion in a highly mobile inflammatory cell population.
Compositions And Methods For Treating Lung Disorders
US Patent:
2011016, Jun 30, 2011
Filed:
Jun 22, 2009
Appl. No.:
13/000603
Inventors:
John E. Repine - Denver CO, US
International Classification:
A61K 31/4164, A61K 31/385, G01N 33/53, A61P 11/00
US Classification:
514401, 514440, 435 721
Abstract:
The present invention relates to methods of treating subjects with alveolar capillary membrane injury or methods of preventing alveolar capillary membrane injury in subjects, with the methods comprising administering to the subjects a therapeutically effective amount of ergothioneine and a pharmaceutically acceptable carrier. The invention also relates to methods of screening candidate compounds for their ability to mitigate the effects of alveolar capillary membrane injury.